

PSA-values from clinical prostate trial mentioned on SpectraCure presentation at "Stora Aktiedagen" in Stockholm

On November 13, SpectraCure made a company presentation when Aktiespararna arranged "Stora Aktiedagen" at Sheraton Hotel in Stockholm. SpectraCure are currently performing a clinical Phase 1 trial for treatment of patients with recurrent prostate cancer, using the company's tumour treatment technique photodynamic therapy (PDT). During the presentation, Johannes Swartling, CTO at SpectraCure, mentioned that the PSA values for patient 2 has decreased from 1.4 ng/ml to 0.36 ng/ml after the treatment, indicating that the treatment has had effect. Patient 2 was treated with an intermediate drug dose. As previously reported, the PSA level for patient 3, treated with the highest drug dose, has decreased from 4.9 ng/ml before the treatment to 0.3 ng/ml after the treatment.

It should be noted that the results are preliminary. The effect on the cancer tumours will be continuously evaluated during the follow-up of the patients through PSA-tests, one more magnetic resonance imaging, and tissue biopsies, in accordance with a protocol established in advance.

For further information, contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.